Form 4: Xenon Pharmaceuticals Executive Sells Shares
Insider Transaction (Form 4)
Christopher John Kenney, Chief Medical Officer of Xenon Pharmaceuticals Inc., sold 7,068 shares of common stock on August 28, 2026.
Summary
- Open-market sale: disposed of 6,368 Common Shares at $60.17 ($383,145) on August 28, 2026; holds 702 after (Direct).
- Open-market sale: disposed of 700 Common Shares at $60.98 ($42,684) on August 28, 2026; holds 2 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $425,829 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Christopher John Kenney — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-28 | Open-market sale | Common Shares | 6,368 | $60 | $383.1K | 702 |
| 2026-08-28 | Open-market sale | Common Shares | 700 | $61 | $42.7K | 2 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-28 | Open-market sale (6,368 shares) |
| 2026-08-28 | Open-market sale (700 shares) |
Keywords
insider transaction, Form 4, XENE, Xenon Pharmaceuticals Inc., bearish, Christopher John Kenney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.